Cargando…
Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520476/ https://www.ncbi.nlm.nih.gov/pubmed/31012051 http://dx.doi.org/10.1007/s40264-019-00816-3 |
| _version_ | 1783418747702214656 |
|---|---|
| author | Ghosh, Subrata Gensler, Lianne S. Yang, Zijiang Gasink, Chris Chakravarty, Soumya D. Farahi, Kamyar Ramachandran, Paraneedharan Ott, Elyssa Strober, Bruce E. |
| author_facet | Ghosh, Subrata Gensler, Lianne S. Yang, Zijiang Gasink, Chris Chakravarty, Soumya D. Farahi, Kamyar Ramachandran, Paraneedharan Ott, Elyssa Strober, Bruce E. |
| author_sort | Ghosh, Subrata |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6520476 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65204762019-06-05 Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs Ghosh, Subrata Gensler, Lianne S. Yang, Zijiang Gasink, Chris Chakravarty, Soumya D. Farahi, Kamyar Ramachandran, Paraneedharan Ott, Elyssa Strober, Bruce E. Drug Saf Correction Springer International Publishing 2019-04-22 2019 /pmc/articles/PMC6520476/ /pubmed/31012051 http://dx.doi.org/10.1007/s40264-019-00816-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Correction Ghosh, Subrata Gensler, Lianne S. Yang, Zijiang Gasink, Chris Chakravarty, Soumya D. Farahi, Kamyar Ramachandran, Paraneedharan Ott, Elyssa Strober, Bruce E. Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs |
| title | Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs |
| title_full | Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs |
| title_fullStr | Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs |
| title_full_unstemmed | Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs |
| title_short | Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs |
| title_sort | correction to: ustekinumab safety in psoriasis, psoriatic arthritis, and crohn’s disease: an integrated analysis of phase ii/iii clinical development programs |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520476/ https://www.ncbi.nlm.nih.gov/pubmed/31012051 http://dx.doi.org/10.1007/s40264-019-00816-3 |
| work_keys_str_mv | AT ghoshsubrata correctiontoustekinumabsafetyinpsoriasispsoriaticarthritisandcrohnsdiseaseanintegratedanalysisofphaseiiiiiclinicaldevelopmentprograms AT genslerliannes correctiontoustekinumabsafetyinpsoriasispsoriaticarthritisandcrohnsdiseaseanintegratedanalysisofphaseiiiiiclinicaldevelopmentprograms AT yangzijiang correctiontoustekinumabsafetyinpsoriasispsoriaticarthritisandcrohnsdiseaseanintegratedanalysisofphaseiiiiiclinicaldevelopmentprograms AT gasinkchris correctiontoustekinumabsafetyinpsoriasispsoriaticarthritisandcrohnsdiseaseanintegratedanalysisofphaseiiiiiclinicaldevelopmentprograms AT chakravartysoumyad correctiontoustekinumabsafetyinpsoriasispsoriaticarthritisandcrohnsdiseaseanintegratedanalysisofphaseiiiiiclinicaldevelopmentprograms AT farahikamyar correctiontoustekinumabsafetyinpsoriasispsoriaticarthritisandcrohnsdiseaseanintegratedanalysisofphaseiiiiiclinicaldevelopmentprograms AT ramachandranparaneedharan correctiontoustekinumabsafetyinpsoriasispsoriaticarthritisandcrohnsdiseaseanintegratedanalysisofphaseiiiiiclinicaldevelopmentprograms AT ottelyssa correctiontoustekinumabsafetyinpsoriasispsoriaticarthritisandcrohnsdiseaseanintegratedanalysisofphaseiiiiiclinicaldevelopmentprograms AT stroberbrucee correctiontoustekinumabsafetyinpsoriasispsoriaticarthritisandcrohnsdiseaseanintegratedanalysisofphaseiiiiiclinicaldevelopmentprograms |